Schiavi Paolo, Laccarino Corrado, Servadei Franco
Unit of Neurosurgery-Neurotraumatology, University Hospital of Parma, Parma, Italy.
Acta Biomed. 2012 Apr;83(1):5-20.
From the first study in 1995 the role of calcium-binding protein S100B in Traumatic Brain Injury (TBI) has been variously investigated in many clinical works. The aim of this work is to analyze the recent published reports with a reference to serum and CSF levels and to identify a possible role of S100 in the management ofTBI.
A MEDLINE search with a various number of query related to "S100" and "TBI" was performed from 2000 to 2011. All identified articles and abstracts have been reviewed.
Serum and CSF samples of the marker well correlate in most of the papers to the degree of intracranial injury as determined by CT scans. Furthermore patients with the higher levels of S100B show a worse prognosis. In the paediatric age a relationship with the outcomes in spite of difficulties to determine normal values is also observed. Some proposal about a clinical use of S100B to decrease the number of neuroradiological examinations are present.
S100B shows some interesting potentialities, but we have not enough evidence to insert this marker of brain damage in the protocols for management of TBI. However its use in experts' hands in association with others clinical and radiological features may help to improve medical practice in the treatment of TBI.
自1995年的第一项研究以来，钙结合蛋白S100B在创伤性脑损伤（TBI）中的作用已在许多临床研究中得到了广泛研究。这项工作的目的是分析最近发表的关于血清和脑脊液水平的报告，并确定S100在TBI管理中的可能作用。
从2000年到2011年，使用与“S100”和“TBI”相关的各种查询词在MEDLINE数据库中进行检索。对所有检索到的文章和摘要进行了综述。
在大多数论文中，该标志物的血清和脑脊液样本与CT扫描确定的颅内损伤程度密切相关。此外，S100B水平较高的患者预后较差。在儿童年龄组中，尽管难以确定正常值，但也观察到了与预后的关系。关于使用S100B减少神经放射学检查次数的一些建议也存在。
S100B显示出一些有趣的潜力，但我们没有足够的证据将这种脑损伤标志物纳入TBI管理方案中。然而，在专家手中将其与其他临床和放射学特征结合使用可能有助于改善TBI治疗中的医疗实践。
